Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN. Goetz MP, et al. Among authors: mcgovern rm. J Clin Oncol. 2017 Oct 20;35(30):3391-3400. doi: 10.1200/JCO.2017.73.3246. Epub 2017 Aug 30. J Clin Oncol. 2017. PMID: 28854070 Free PMC article. Clinical Trial.
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Jayaraman S, Hou X, Kuffel MJ, Suman VJ, Hoskin TL, Reinicke KE, Monroe DG, Kalari KR, Tang X, Zeldenrust MA, Cheng J, Bruinsma ES, Buhrow SA, McGovern RM, Safgren SL, Walden CA, Carter JM, Reid JM, Ingle JN, Ames MM, Hawse JR, Goetz MP. Jayaraman S, et al. Among authors: mcgovern rm. Breast Cancer Res. 2020 May 19;22(1):51. doi: 10.1186/s13058-020-01286-7. Breast Cancer Res. 2020. PMID: 32430040 Free PMC article.
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. Goetz MP, et al. Among authors: mcgovern rm. Invest New Drugs. 2013 Dec;31(6):1559-67. doi: 10.1007/s10637-013-0034-9. Epub 2013 Oct 10. Invest New Drugs. 2013. PMID: 24114122 Free PMC article. Clinical Trial.
Skeletal and Uterotrophic Effects of Endoxifen in Female Rats.
Gingery A, Iwaniec UT, Subramaniam M, Turner RT, Pitel KS, McGovern RM, Reid JM, Marler RJ, Ingle JN, Goetz MP, Hawse JR. Gingery A, et al. Among authors: mcgovern rm. Endocrinology. 2017 Oct 1;158(10):3354-3368. doi: 10.1210/en.2016-1871. Endocrinology. 2017. PMID: 28977607 Free PMC article.
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors.
Takebe N, Coyne GO, Kummar S, Collins J, Reid JM, Piekarz R, Moore N, Juwara L, Johnson BC, Bishop R, Lin FI, Mena E, Choyke PL, Lindenberg ML, Rubinstein LV, Bonilla CM, Goetz MP, Ames MM, McGovern RM, Streicher H, Covey JM, Doroshow JH, Chen AP. Takebe N, et al. Among authors: mcgovern rm. Oncotarget. 2021 Feb 16;12(4):268-277. doi: 10.18632/oncotarget.27887. eCollection 2021 Feb 16. Oncotarget. 2021. PMID: 33659039 Free PMC article.
Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors.
Koubek EJ, Ralya AT, Larson TR, McGovern RM, Buhrow SA, Covey JM, Adjei AA, Takebe N, Ames MM, Goetz MP, Reid JM. Koubek EJ, et al. Among authors: mcgovern rm. J Clin Pharmacol. 2022 Sep;62(9):1121-1131. doi: 10.1002/jcph.2053. Epub 2022 Apr 19. J Clin Pharmacol. 2022. PMID: 35358345 Free PMC article.
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC. Jaeckle KA, et al. Among authors: mcgovern rm. J Neurooncol. 2010 Aug;99(1):73-80. doi: 10.1007/s11060-009-0103-2. Epub 2010 Jan 9. J Neurooncol. 2010. PMID: 20063115 Free PMC article. Clinical Trial.
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. Villablanca JG, et al. Among authors: mcgovern rm. Clin Cancer Res. 2011 Nov 1;17(21):6858-66. doi: 10.1158/1078-0432.CCR-11-0995. Epub 2011 Sep 9. Clin Cancer Res. 2011. PMID: 21908574 Free PMC article. Clinical Trial.
58 results